THE EFFECTIVENESS OF PHOTODYNAMIC THERAPY (PDT) WITH VERTEPORFIN IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION (ARMD) AND UNDERSTAND ALL FEATURES OF VERTEPORFIN FOR OBJECTIVE ADVISING TO UKRAINIAN PATIENTS

Year 2022, Volume: 8 Issue: 2, 43 - 60, 03.09.2022

Ayhan Önal

Abstract

In this study a systematic review of the clinical effectiveness of PDT compared with current practice was undertaken. Searches in Macular degeneration Network, Investigative Ophthalmology and Visual Science, Medline, Embase-Elsevier, the Cochrane Library and the Internet, updated to January 2007, revealed the Treatment of ARMD with Photodynamic Therapy (TAP) and the Verteporfin in Photodynamic Therapy (VIP) fully published, and other few ongoing randomized controlled trials. The overall incidence of study eye adverse events was not significantly different between verteporfin and placebo. Verteporfin-treated patients did not experience development of more subretinal hemorrhage, fibrosis, or atrophy of the retinal pigment epithelium than did placebo-treated patients. No difference in VA between verteporfin-treated patients and controls was noted when the area of classic choroidal neovascularization (CNV) was more than 0% but less than 50% of the area of the entire lesion (termed minimally classic CNV lesions). However, minimally classic CNV lesions receiving verteporfin therapy were less likely to show progression of classic CNV beyond the area of the lesion at baseline, to have fluorescein leakage from classic CNV and to have a lesion size more than six disc areas compared to those receiving placebo. Verteporfin in combination with PDT should only be used by retinal specialists experienced in the management of ARMD and in diagnosis of classic CNV using fluorescein angiography (FA). Verteporfin in combination with photodynamic therapy may be used to treat patients with predominantly classic subfoveal CNV secondary to ARMD.

Keywords

Verteporfin and ARMD, exudative age-related macular degeneration and PDT with verteporfin, subfoveal ARMD and verteporfin

References

• 1. Freil JP (ed.) Dorland's Illustrated Medical Dictionary, 25th Edition, Philedelphia; 1974: 414-415.
• 2. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R, et al. The international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group: Surv Ophthalmol 1995; 39:367 -74.
• 3. Kubo N, Ohno Y, Yanagawa H et al. Annual estimated number of patients with senile disciform macular degeneration in Japan. The Ministry of Health and Welfare in Japan. Tokyo, Japan: 1989, p 136.
• 4. Ambati, J. et al. (2003).An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat. Med. 9, 1390–1397
• 5. Stone EM, Lotery AJ, Munier FL, et al: A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nat Genet 1999 Jun; 22(2): 199-202[Medline].
• 6. Alexander, Larry J. Primary Care of the Posterior Segment 2nd Ed. Appleton & Lange. 1994.
• 7. Kahn HA, Leibowitz HM, Ganley JP. The Framingham Eye Study, I: outline and major prevalence findings. Am J Epidemiol 1977 Jul; 106(1): 17-32[Medline].
• 8. Attebo K, Mitchell P, Smith W: Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. Ophthalmology 1996 Mar; 103(3): 357-64[Medline].
• 9. Mozaffarieh M, Sacu S, Wedrich A. The role of the carotenoids, lutein and zeaxanthin, in protecting against age-related macular degeneration: A review based on controversial evidence. Nutr J. 2003; 2: 20.
• 10. AMD Alliance International. Awareness research. Available at: http://www.amDALLIANCE.ORG/ amd/awareness research.html (accessed 1999).
• 11. World Health Organization. Fact sheet No. 144.Blindness and visual disability. Part III of VII: other leading causes worldwide. www.who.int/inf-fs/en/fact144html (accessed Dec 2002).
• 12. Pizzarello LD. The dimensions of the problem of eye disease among the elderly. Ophthalmology 1987; 94:1191–5.
• 13. Hyman L, Schachat AP, He Q, Leske MC. Hypertension, cardiovascular disease, and age-related macular degeneration. Age-Related Macular Degeneration Risk Factors Study Group. Arch Ophthalmol 2000; 118:351-8.
• 14. Eagle RC: Mechanisms of maculopathy. Ophthalmology 1984 Jun; 91(6): 613-25[Medline].
• 15. American Family Physician 2000; 61:3035-42.
• 16. Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year result of 2 randomized clinical trials TAP report 2. Arch Ophthalmol 2001; 119: 198-207[Abstract/Free Full Text].
• 17. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials—TAP report No 1.Arch Ophthalmol 1999; 117: 1329-1345.
• 18. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: Two year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-Verteporfin in Photodynamic therapy report 2: Am. J Ophthalmol 2001; 131: 541-560.
• 19. Houle JM, Strong A. Clinical pharmacokinetics of verteporfin. J Clin Pharmacol 2002; 42:547–557.
• 20. Arnold JJ, Blinder KJ, Bressler NM, Bressler SB, Burdan A, Haynes L, Lim JI, Miller JW, Potter MJ, Reaves A, et al: Acute severe visual acuity decrease after photodynamic therapy with verteporfin: Case reports from randomized clinical trials—TAP and VIP report no. 3. Am. J Ophthalmol 2004; 137: 683-696.
• 21. Arnold JJ, Sarks H. Extracts from ‘clinical evidence’ Age related macular degeneration: BMJ 2000; 321:741–4.
• 22. Anon. Verteporfin in combination with laser therapy: helpful in some forms of age-related macular degeneration. Prescrire Int 2001; 10:78–81[Medline].
• 23. Wormald R, Evans J, Smeeth L, et al. Photodynamic therapy for neovascular age related macular degeneration. The Cochrane Library 2001; 2001:1–13.
• 24. Visudyne® (verteporfin for injection) [package insert]. Duluth, GA: Novartis Ophthalmics, Inc; 2002.Avaible at: http://www.qltinc.com/Qltinc/_downloads/commercial/US_Package_Insert.pdf: Accessed January 14, 2004.
• 25. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization pathologic myopia with verteporfin: 1 year results of a randomized clinical trial—VIP Report No. 1. Ophthalmology 2001; 108:841–852.
• 26. Lear J, Rajapakse R, Pohl J. Low back pain associated with streptokinase: Lancet 1992; 340: 851 (letter).
• 27. Sculier JP, Coune A, Brassinne C, et al. Intravenous infusion of high doses of liposomes containing NSC 251635, a water-insoluble cytostatic agent: A pilot study with pharmacokinetic data. J Clin Oncol 1986; 4:789 -797.
• 28. Hui YF, Cortes JE. Chest and back pain associated with a six-hour infusion of liposomal daunorubicin. Ann Pharmacother 2000; 34:810–811.
• 29. Skubitz KM, Skubitz AP. Mechanism of transient dyspnea induced by pegylated-liposomal doxorubicin (Doxil): Anticancer Drugs 1998; 9:45–50.
• 30. Borodoker N, Spaide RF, Maranan L, et al. Verteporfin infusion-associated pain. Am. J Ophthalmol 2002; 133:211–214.
• 31. Cunningham CM, Kingzette M, Richards RL, Alving CR, Lint TF, Gewurz H. Activation of human complement by liposomes: A model for membrane activation of the alternative pathway: J Immunol 1979; 122:1237–1242.
• 32. Chonn A, Cullis PR, Devine DV. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes: J Immunol 1991; 146: 4234–4241.
• 33. Devin DV, Wong K, Serrano K, Chonn A, Cullis PR. Liposome-complement interactions in rat serum: Implications for liposome survival studies. Biochim Biophys Acta 1994; 1191:43–51.
• 34. Szebeni J, Wassef NM, Rudolph AS, Alving CR. Complement activation by liposome-encapsulated hemoglobin invitro: The role of endotoxin contamination: Artif Cells Blood Substit Immobil Biotechnol 1995; 23: 355–363.
• 35. Spaide RF, Maranan L. Neutrophil margination as a possible mechanism for verteporfin infusion-associated pain. Am. J Ophthalmol 2003; 135: 549–550.
• 36. Houle JM, Strong HA: Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin: Retina 2002; 22: 691–697
• 37. American Cancer Society. Cancer Facts and Figures, 2002, Atlanta, GA: American Cancer Society, 2002. Available at: http://www.cancer.org/downloads/STT/CancerFacts&Figures2002TM.pdf: Accessed December 11, 2003.
• 38. Winawer SJ, Natural history of colorectal cancer. Am. J. Med. 1999; 106(1A): 3S–6S, 50S–51S.
• 39. Retina, the Journal of Retinal and Vitreous Diseases, 2004, Volume 24: 1-12
• 40. Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Mones JM, Potter MJ, et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: Three-year results of an open-label extension of 2 randomized clinical trials—TAP report no. 5. Arch Ophthalmol 2002; 120: 1307-1314.
• 41. TAP study group: Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration, additional information regarding baseline lesion composition’s impact on vision outcomes, TAP report 3. Arch Ophthalmol 2002; 2002: 1443–54.
• 42. 186. Rubin GS, Bressler NM, TAP study group. Effects of verteporfin therapy on contrast sensitivity. Results from the treatment of age related macular degeneration with photodynamic therapy (TAP) investigation, TAP report 4. Retina 2002; 22: 536–44[CrossRef][Medline].
• 43. Royal College of Ophthalmologists: Guidelines for photodynamic therapy. August 2000: Cited at www.rcophth.ac.uk/publications/guidelines/photodynamic_therapy.html: 13.10.00.